Equities

Nuformix PLC

NFX:LSE

Nuformix PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.23
  • Today's Change-0.01 / -4.17%
  • Shares traded57.31m
  • 1 Year change212.29%
  • Beta2.4629
Data delayed at least 20 minutes, as of Feb 06 2026 16:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Nuformix plc is a United Kingdom-based pharmaceutical development company, which is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurpose. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its pipeline includes NXP001, NXP002 and NXP004. NXP001 is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis. NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation and has since secured similar approvals in breast, pancreatic and prostate cancers.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-652.59k
  • Incorporated2015
  • Employees3.00
  • Location
    Nuformix PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
  • Phone+44 12 2362 7222
  • Websitehttps://nuformix.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Kanabo Group PLC1.14m-8.18m1.42m17.001.42m17.00
BSF Enterprise PLC24.09k-1.60m2.57m4.002.57m4.00
Nuformix PLC0.00-652.59k4.85m3.004.85m3.00
CRISM' Therapeutics Corp25.00k-1.49m6.60m0.006.60m0.00
Oxford Biodynamics PLC1.10m-11.15m12.01m44.0012.01m44.00
Probiotix Health PLC2.22m-736.00k12.26m4.0012.26m4.00
CRUSHMETRIC Group Ltd-100.00bn-100.00bn20.62m17.0020.62m17.00
Data as of Feb 06 2026. Currency figures normalised to Nuformix PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.